This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Other lower respiratory disease
  • /
  • Role and New Insights of Pirfenidone in Fibrotic D...

Role and New Insights of Pirfenidone in Fibrotic Diseases.

Read time: 1 mins
Published:14th Oct 2015
Author: Lopez-de la Mora DA, Sanchez-Roque C, Montoya-Buelna M, Sanchez-Enriquez S, Lucano-Landeros S, Macias-Barragan J et al.
Availability: Free full text
Ref.:Int J Med Sci. 2015;12(11):840-7.

Pirfenidone (PFD) is a non-peptide synthetic molecule issued as a broad-spectrum anti-fibrotic drug with the ability to decrease TGF-β1, TNF-α, PDGF and COL1A1 expression, which is highly related to prevent or remove excessive deposition of scar tissue in several organs. Basic and clinical evidence suggests that PFD may safely slow or inhibit the progressive fibrosis swelling after tissue injuries.

Furthermore, a number of evidence suggests that this molecule will have positive effects in the treatment of other inflammatory diseases. This review contains current research in which PFD has been used as the treatment of several diseases, and focus mainly in the outcomes related to improve inflammation and fibrogenesis. Therefore, the main goal of this review is to focus on the novel findings of PFD efficacy rather than deepen in the chemical aspects of the molecule.


Read abstract on library site

Access full article